Advertisement


Jonathan W. Friedberg, MD: Marginal Zone Lymphoma Therapy Update

2016 Pan Pacific Lymphoma Conference

Advertisement

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses the use of rituximab as a single agent and in combination with chemotherapy, the emerging role of novel agents, and some possible explanations for the small subset of patients with inferior outcomes.



Related Videos

Lymphoma

Steven M. Horwitz, MD, on Sequencing New Agents in Relapsed Peripheral T-Cell Lymphoma

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, reviews the data supporting current treatment approaches for T-cell lymphomas and discusses the specific subtype criteria used to individualize therapy.

Lymphoma

Julie M. Vose, MD, MBA, on Highlights of Pan Pacific Lymphoma 2016

Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses the key presentations at the 2016 Pan Pacific Lymphoma Conference.

Lymphoma

John G. Gribben, MD, DSc, on Follicular Lymphoma: Still a Role for Transplant?

John G. Gribben, MD, DSc, of Barts Cancer Institute, discusses the pros and cons of both autologous and allogeneic stem cell transplantation in follicular lymphoma, and the challenges of selecting the right patients for these procedures.

Lymphoma

Stephen M. Ansell, MD, PhD, on Precision Immunotherapy for Refractory Hodgkin Lymphoma

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the role of checkpoint inhibitors in Hodgkin lymphoma and the efficacy of nivolumab and pembrolizumab.

Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, on Managing Multiple Myeloma

Beth M. Faiman, PhD, MSN, CNP, AOCN, of the Cleveland Clinic, discusses working with patients with multiple myeloma to minimize the toxicity of their treatment and improve their outcomes.

Advertisement

Advertisement




Advertisement